LRIG1 Improves Chemosensitivity Through Inhibition of BCL-2 and MnSOD in Glioblastoma

详细信息    查看全文

• 作者：Jianjun Ding (1) (3)
  Baohui Liu (2)
  Yi He (3)
  Xianhou Yuan (1)
  Daofeng Tian (2)
  Baowei Ji (2)
  Long Wang (2)
  Liquan Wu (2)
  Huimin Dong (2)
  Junmin Wang (2)
  Xiaonan Zhu (2)
  Qiang Cai (2)
  Shenqi Zhang (2)
  Qianxue Chen (2)
  
  1. Zhongnan Hospital ; Wuhan University ; 125 Donghu Street ; Wuhan ; 430071 ; Hubei ; China
  3. The Second Renmin Hospital of Shenzhen ; 3002 Yigangxi Street ; Shenzhen ; 518039 ; Guangdong ; China
  2. Renmin Hospital ; Wuhan University ; 238 Jiefang Street ; Wuhan ; 430060 ; Hubei ; China
  
• 关键词：Leucine ; rich repeats and immunoglobulin ; like domains 1 (LRIG1) ; Chemosensitivity ; B cell lymphoma 2 (BCL ; 2) ; Manganese superoxide dismutase (MnSOD)
• 刊名：Cell Biochemistry and Biophysics
• 出版年：2015
• 出版时间：January 2015
• 年：2015
• 卷：71
• 期：1
• 页码：27-33
• 全文大小：353 KB
• 参考文献：1. Nikiforova, M. N., & Hamilton, R. L. (2011). Molecular diagnostics of gliomas. / Archives of Pathology and Laboratory Medicine, / 135(5), 558鈥?68.
  2. Nikaki, A., Piperi, C., & Papavassiliou, A. G. (2012). Role of microRNAs in gliomagenesis: Targeting miRNAs in glioblastoma multiforme therapy. / Expert Opinion on Investigational Drugs, / 21(10), 1475鈥?488. CrossRef
  3. Spinelli, G. P., et al. (2012). Chemotherapy and target therapy in the management of adult high-grade gliomas. / Current Cancer Drug Targets, / 12(8), 1016鈥?031. CrossRef
  4. Sun, S., et al. (2012). Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide. / Journal of Neuro-Oncology, / 109(3), 467鈥?75. CrossRef
  5. Alla, V., et al. (2012). E2F1 confers anticancer drug resistance by targeting ABC transporter family members and BCL-2 via the p73/DNp73-miR-205 circuitry. / Cell Cycle, / 11(16), 3067鈥?078. CrossRef
  6. Greaves, W., et al. (2012). Detection of ABCC1 expression in classical Hodgkin lymphoma is associated with increased risk of treatment failure using standard chemotherapy protocols. / Journal of Hematology & Oncology, / 5, 47. CrossRef
  7. Herraez, E., et al. (2012). Cisplatin-induced chemoresistance in colon cancer cells involves FXR-dependent and FXR-independent up-regulation of ABC proteins. / Molecular Pharmaceutics, / 9(9), 2565鈥?576. CrossRef
  8. Michalak, K., & Wesolowska, O. (2012). Polyphenols counteract tumor cell chemoresistance conferred by multidrug resistance proteins. / Anti-Cancer Agents in Medicinal Chemistry, / 12(8), 880鈥?90. CrossRef
  9. Minami, T., et al. (2012). HER2 as therapeutic target for overcoming ATP-binding cassette transporter-mediated chemoresistance in small cell lung cancer. / Molecular Cancer Therapeutics, / 11(4), 830鈥?41. CrossRef
  10. Tian, C., et al. (2012). Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: A Gynecologic Oncology Group study. / Gynecologic Oncology, / 124(3), 575鈥?81. CrossRef
  11. Nilsson, J., et al. (2001). Cloning, characterization, and expression of human LIG1. / Biochemical and Biophysical Research Communications, / 284(5), 1155鈥?161. CrossRef
  12. Holmlund, C., et al. (2004). Characterization and tissue-specific expression of human LRIG2. / Gene, / 332, 35鈥?3. CrossRef
  13. Guo, D., et al. (2004). The LRIG gene family has three vertebrate paralogs widely expressed in human and mouse tissues and a homolog in Ascidiacea. / Genomics, / 84(1), 157鈥?65. CrossRef
  14. Suzuki, Y., et al. (1996). cDNA cloning of a novel membrane glycoprotein that is expressed specifically in glial cells in the mouse brain. LIG-1, a protein with leucine-rich repeats and immunoglobulin-like domains. / Journal of Biological Chemistry, / 271(37), 22522鈥?2527. CrossRef
  15. Yi, W., et al. (2009). Expression of leucine-rich repeats and immunoglobulin-like domains (LRIG) proteins in human ependymoma relates to tumor location, WHO grade, and patient age. / Clinical Neuropathology, / 28(1), 21鈥?7. CrossRef
  16. Liu, B., Chen, Q., Tian, D., Wu, L., Wang, J., Cai, Q., et al. (2011). Increased leucine-rich repeats and immunoglobulin-like domains 1 expression enhances chemosensitivity. / Neural Regeneration Research, / 6(32), 2516鈥?520.
  17. Johnson, D. R., & Chang, S. M. (2012). Recent medical management of glioblastoma. / Advances in Experimental Medicine and Biology, / 746, 26鈥?0. CrossRef
  18. Higgins, C. F. (2007). Multiple molecular mechanisms for multidrug resistance transporters. / Nature, / 446(7137), 749鈥?57. CrossRef
  19. Jennings, M. T., & Iyengar, S. (2001). The molecular genetics of therapeutic resistance in malignant astrocytomas. / The American Journal of Pharmacogenomics, / 1(2), 93鈥?9. CrossRef
  20. Stupp, R., et al. (2007). Chemoradiotherapy in malignant glioma: Standard of care and future directions. / Journal of Clinical Oncology, / 25(26), 4127鈥?136. CrossRef
  21. Lu, C., & Shervington, A. (2008). Chemoresistance in gliomas. / Molecular and Cellular Biochemistry, / 312(1鈥?), 71鈥?0. CrossRef
  22. Wang, X., et al. (2012). LRIG1 enhances cisplatin sensitivity of glioma cell lines. / Oncology Research, / 20(5鈥?), 205鈥?11. CrossRef
  23. Desjardins, A., Reardon, D. A., & Vredenburgh, J. J. (2009). Current available therapies and future directions in the treatment of malignant gliomas. / Biologics, / 3, 15鈥?5.
  24. Johansson, M., et al. (2013). The soluble form of the tumor suppressor LRIG1 potently inhibits in vivo glioma growth irrespective of EGF receptor status. / Neuro-Oncology, / 15(9), 1200鈥?211. CrossRef
  25. Yang, C. H., et al. (2013). Pulsed radiofrequency treatment attenuates increases in spinal excitatory amino acid release in rats with adjuvant-induced mechanical allodynia. / NeuroReport, / 24(8), 431鈥?36.
  26. Yi, W., et al. (2011). Paracrine regulation of growth factor signaling by shed leucine-rich repeats and immunoglobulin-like domains 1. / Experimental Cell Research, / 317(4), 504鈥?12. CrossRef
  27. Ye, F., et al. (2009). Upregulation of LRIG1 suppresses malignant glioma cell growth by attenuating EGFR activity. / Journal of Neuro-Oncology, / 94(2), 183鈥?94. CrossRef
  28. Stutz, M. A., et al. (2008). LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII. / Oncogene, / 27(43), 5741鈥?752. CrossRef
  29. Griguer, C. E., & Oliva, C. R. (2011). Bioenergetics pathways and therapeutic resistance in gliomas: Emerging role of mitochondria. / Current Pharmaceutical Design, / 17(23), 2421鈥?427. CrossRef
  30. Decleves, X., et al. (2006). Role of ABC transporters in the chemoresistance of human gliomas. / Current Cancer Drug Targets, / 6(5), 433鈥?45. CrossRef
  31. Sodani, K., et al. (2012). GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance. / Biochemical Pharmacology, / 83(12), 1613鈥?622. CrossRef
  32. Ng, W. H., et al. (2009). Glial cell-line derived neurotrophic factor (GDNF) family of ligands confer chemoresistance in a ligand-specific fashion in malignant gliomas. / Journal of Clinical Neuroscience, / 16(3), 427鈥?36. CrossRef
  
• 刊物主题：Biochemistry, general; Pharmacology/Toxicology; Biotechnology; Cell Biology; Biophysics and Biological Physics;
• 出版者：Springer US
• ISSN：1559-0283

文摘

We have reported that Leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) can improve the chemosensitivity in U251 cells. However, the underlying mechanisms how LRIG1 improves the chemosensitivity remain unknown. In this study, we reported that LRIG1 can improve the chemosensitivity through the inhibition of B cell lymphoma 2 (BCL-2) and manganese superoxide dismutase (MnSOD). In addition, we showed that the expression level of LRIG1 was significantly negatively correlated with BCL-2 and MnSOD expression in glioma. Our research demonstrated that overexpression of LRIG1 can enhance the chemosensitivity. BCL-2 and MnSOD were inhibited in LRIG1 overexpressing cells. On the other hand, when BCL-2 and MnSOD were knocked down, the chemosensitivity of U251 cells decreased, and the effect of LRIG1 in regulating chemosensitivity was compromised. For the first time, our results showed that LRIG1 can enhance chemosensitivity in glioblastoma by inhibition of BCL-2 and MnSOD.